Search results
Whose health matters? The diversity deficit in clinical trials - EconoTimes
EconoTimes· 3 days agoThe gold standard for clinical trials — randomized controlled studies — often require thousands of...
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
Motley Fool via Yahoo Finance· 6 days agos newer diabetes medicines is Mounjaro, first approved in the U.S. in May 2022. Mounjaro is a...
New $100M tower planned for Medical Center - San Antonio Business Journal
The Business Journals· 20 hours agoThe $100 million structure, dubbed Science One, will house expanded research activities tied to cancer, aging, brain diseases, obesity and diabetes. UT Health San Antonio ...
Ozempic and Wegovy could soon be challenged by China’s generic competitors
Fast Company Magazine· 2 days agoNovo Nordisk is facing the prospect of intensifying competition in the promising Chinese market...
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Zacks via Yahoo Finance· 22 hours agoLast year, positive data from a late-stage study evaluating Novo Nordisk’s new diabetes drug,...
Elizabeth Holmes’ appeal set to be heard June 11 in federal court
San Jose Mercury News· 4 days agoThe notorious founder of the now-defunct Palo Alto blood-testing startup is serving a lengthy...
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030 | The Motley Fool
The Motley Fool· 6 days agoEli Lilly and Novo Nordisk are rivals in the drug market for diabetes treatment, a competition that...
High price of popular diabetes drugs deprives low-income people of effective treatment
New Hampshire Union Leader· 7 days agoFor the past year and a half, Tandra Cooper Harris and her husband, Marcus, who both have diabetes,...
Analysis | Weight-loss drugs are so popular they’re headed for Medicare negotiations
Washington Post· 1 day agoToday’s edition: Conservative policymakers with ties to former president Donald Trump want to limit...
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
The Motley Fool via AOL· 6 days agos newer diabetes medicines is Mounjaro, first approved in the U.S. in May 2022. Mounjaro is a therapy with a novel mechanism of action that generated an $5 billion ...